证券代码：600833 证券简称：第一医药 公告编号：临 2025-036 上海第一医药股份有限公司 关于增加指定信息披露媒体的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 为扩大上海第一医药股份有限公司（以下简称公司）信息披露覆盖面，进一步做好 投资者关系管理工作，公司决定自本公告披露之日起，增加《证券时报》为指定信息披 露媒体。增加后，公司的指定信息披露媒体为《上海证券报》《证券时报》及上海证券 交易所网站（www.sse.com.cn）。 公司所有公开披露的信息均以在上述指定信息披露媒体刊登的正式公告为准，敬请 广大投资者理性投资，注意投资风险。 特此公告。 上海第一医药股份有限公司董事会 2025 年 8 月 2 日 ...

金融界消息 截至2025年7月31日收盘，第一医药（600833）报收于13.17元，下跌3.23%，换手率 3.76%，成交量8.38万手，成交金额1.11亿元。 资金流向方面，今日主力资金净流出1154.09万元，占比成交额10.35%。其中，超大单净流出544.72万 元、占成交额4.89%，大单净流出609.37万元、占成交额5.47%，中单净流出流入647.69万元、占成交额 5.81%，小单净流入506.40万元、占成交额4.54%。 第一医药最新一期业绩显示，截至2025一季报，公司营业总收入5.04亿元、同比增长9.07%，归属净利 润473.91万元，同比减少86.86%，扣非净利润449.55万元，同比增长1.13%，流动比率1.811、速动比率 1.235、资产负债率42.21%。 通过天眼查大数据分析，上海第一医药股份有限公司共对外投资了20家企业，参与招投标项目16次，知 识产权方面有商标信息38条，专利信息1条，此外企业还拥有行政许可25个。 来源：金融界 天眼查商业履历信息显示，上海第一医药股份有限公司，成立于1992年，位于上海市，是一家以从事零 售业为主的企业。企业注册资本2 ...

上海第一医药股份有限公司（以下简称"公司"）董事会于近日收到公司证券事务 代表奉竹女士的书面辞任报告，奉竹女士因个人原因，申请辞去公司证券事务代表等职 务，辞任报告自送达公司董事会之日起生效。辞任后，奉竹女士不再担任公司任何职务。 上海第一医药股份有限公司董事会 证券代码：600833 证券简称：第一医药 公告编号：临 2025-035 上海第一医药股份有限公司 关于证券事务代表辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 截至本公告日，奉竹女士未持有公司股份，其工作已进行妥善交接，其辞任不会影 响公司正常运行。奉竹女士在任职期间勤勉尽责、恪尽职守。公司董事会对奉竹女士在 任职期间对公司做出的贡献表示衷心感谢！ 根据《上海证券交易所股票上市规则》等相关规定，公司将尽快聘任符合任职资格 的人员担任证券事务代表，协助公司董事会秘书开展相关工作。 特此公告。 2025 年 7 月 19 日 ...

[Shanghai No. 1 Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Shanghai%20No.%201%20Pharmaceutical%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast%20Overview) The company forecasts a significant year-on-year decrease in H1 2025 net profit attributable to shareholders due to prior year non-recurring gains, while core business net profit is projected to grow H1 2025 Performance Forecast | Indicator | H1 2025 Estimated (Ten Thousand RMB) | Year-on-Year Change | | :--- | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | 1,260 to 1,580 | ↓ 87.83% to 90.29% | | **Net Profit Excluding Non-Recurring Gains/Losses** | 800 to 1,000 | ↑ 10.59% to 38.24% | - This performance forecast data is a **preliminary estimate** by the company's finance department and has **not been audited** by a certified public accountant[4](index=4&type=chunk)[5](index=5&type=chunk) [Prior Period Performance Review](index=2&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) The H1 2024 review highlights a large disparity between reported net profit and net profit excluding non-recurring items, setting a high comparison base for the current period H1 2024 Financial Data | Indicator | H1 2024 Amount | | :--- | :--- | | Total Profit | 17,059.20 Ten Thousand RMB | | Net Profit Attributable to Parent Company Shareholders | 12,978.91 Ten Thousand RMB | | Net Profit Excluding Non-Recurring Gains/Losses | 723.37 Ten Thousand RMB | | Earnings Per Share | 0.5818 RMB | [Core Reasons for Performance Change](index=2&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Change) The substantial year-on-year decline in net profit attributable to parent company shareholders is primarily due to a large, one-time housing expropriation compensation in the prior period - The primary reason for the decrease in net profit attributable to parent company shareholders is the **one-time housing expropriation compensation** in the prior period, resulting in a higher comparison base[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) The company states this performance forecast is a preliminary, unaudited estimate by the finance department, with final data potentially differing, but no other major uncertainties are identified - This performance forecast is a **preliminary calculation** by the company's finance department and has **not been audited** by a certified public accountant, thus it contains uncertainties[8](index=8&type=chunk) [Other Explanations](index=2&type=section&id=V.%20Other%20Explanatory%20Matters) The company reiterates that the forecast data is preliminary, and final accurate financial data will be based on the officially disclosed 2025 semi-annual report, advising investor caution - Final financial data will be subject to the company's **officially disclosed 2025 semi-annual report**; investors are advised to be aware of investment risks[9](index=9&type=chunk)

Core Points - The announcement details the election results of the employee director for Shanghai First Pharmaceutical Co., Ltd, with Mr. Hu Liangyu elected as the employee director for the 11th Board of Directors [1] - Mr. Hu Liangyu will serve alongside eight non-employee directors elected at the 2024 annual general meeting, with the term lasting until the end of the 11th Board's tenure [1] Summary by Sections - **Election Results** - Mr. Hu Liangyu has been elected as the employee director for the 11th Board of Directors [1] - The election was conducted in accordance with the Company Law and the company's articles of association [1] - **Director's Profile** - Mr. Hu Liangyu, born in 1980, is a Chinese national with no permanent residency abroad and holds a bachelor's degree [3] - He has held various positions including Secretary of the Youth League Committee at Shanghai Bailian Group and is currently the Deputy Secretary of the Party Committee, Discipline Inspection Commission Secretary, and Chairman of the Labor Union at the company [3] - Mr. Hu has no relationships with the company's directors, senior management, controlling shareholders, or actual controllers, and does not hold any shares in the company [3] - He meets the qualifications to serve as a director of a listed company and has not faced any penalties from the China Securities Regulatory Commission or stock exchanges [3]

Meeting Overview - The shareholders' meeting of Shanghai First Pharmaceutical Co., Ltd. was held on June 20, 2025, at the company's office in Shanghai [1] - The meeting was presided over by Chairman Zhang Haibo and utilized a combination of on-site and online voting methods, complying with relevant laws and regulations [1][3] - A total of 50.2559% of the shares were represented at the meeting [1] Voting Results - A total of 12 proposals were reviewed during the meeting, with proposals 1-7, 9-12 passing by a simple majority, while proposal 8, a special resolution, passed with over two-thirds of the votes [3] - The voting results for the proposals showed a high level of agreement among shareholders, with the majority of votes for each proposal exceeding 99% [2][3] - For example, proposal 1 received 111,862,784 votes in favor, representing 99.7759% of the votes [1][2] Legal Compliance - The meeting's procedures, attendance, and voting processes were confirmed to be in accordance with the Company Law, Securities Law, and other relevant regulations [3][4] - The legal opinions provided by the attending lawyers confirmed the legality and validity of the resolutions passed during the meeting [3][4]

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the 2024 annual general meeting of Shanghai First Pharmaceutical Co., Ltd. [1][5] Group 1: Meeting Organization - The 2024 annual general meeting is scheduled for June 20, 2025, at the third meeting room on the 20th floor of 681 Xiaomuqiao Road, Xuhui District, Shanghai [1][2] - The meeting was announced on May 31, 2025, on the Shanghai Stock Exchange website, detailing the time, location, agenda, attendees, registration methods, and voting procedures [2][3] Group 2: Meeting Attendance - A total of 2 shareholders and their representatives attended the meeting, holding 100,278,034 shares with voting rights, which represents a significant portion of the total voting shares [3][4] - Additionally, 116 shareholders participated through the online voting system during the designated trading hours on June 20, 2025 [4] Group 3: Meeting Proposals - The meeting included several key proposals such as the 2024 Board of Directors' work report, 2024 Supervisory Board's work report, financial reports, profit distribution plan, and various resolutions regarding board member elections and compensation [4][5] - Proposals related to the financial service agreement with Bailian Group and the cancellation of the Supervisory Board were also discussed [4] Group 4: Voting Procedures and Results - The voting results indicated that proposals requiring a two-thirds majority were approved, while others needed a simple majority, with specific votes counted separately for minority investors [5] - The legal opinion confirms that all voting procedures and results comply with relevant laws and regulations, ensuring the legitimacy of the meeting outcomes [5]

Core Points - The company held its first temporary meeting of the 11th Board of Directors on June 20, 2025, with all directors present and no dissenting votes [1][2] - Zhang Haibo was elected as the Chairman of the 11th Board of Directors, with a term starting from the approval date until the end of the board's term [1] - Yao Jun was elected as the Vice Chairman of the 11th Board of Directors, with a similar term duration [1] - The composition of the specialized committees of the 11th Board of Directors was approved, including the Audit Committee, Strategy and ESG Committee, Compensation and Assessment Committee, and Nomination Committee, with all members receiving unanimous support [2] Summary by Categories Board Elections - Zhang Haibo was elected as Chairman with unanimous approval from all 9 directors [1] - Yao Jun was elected as Vice Chairman, also receiving unanimous support [1] Committee Composition - The Audit Committee will consist of Tang Songlian (Chair), Li Jinbiao, Wang Feng, and Chen Shaoxiong [2] - The Strategy and ESG Committee will include Zhang Haibo (Chair), Yao Jun, Zhou Yu, Li Jinbiao, Wang Feng, Tang Songlian, and Chen Shaoxiong [2] - The Compensation and Assessment Committee will be led by Chen Shaoxiong (Chair), with members Zhou Yu, Zhang Rui, Wang Feng, and Tang Songlian [2] - The Nomination Committee will be chaired by Wang Feng, including Zhang Haibo, Hu Liangyu, Tang Songlian, and Chen Shaoxiong [2]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-032 上海第一医药股份有限公司 关于职工董事选举结果的公告 2 上海第一医药股份有限公司董事会 2025 年 6 月 21 日 1 附件：胡良玉先生简历 胡良玉，男，1980 年出生，中国国籍，无境外永久居留权，本科，高级政工师，中 共党员。曾任上海百联集团股份有限公司团委书记，百联集团有限公司团委副书记、团 委书记，本公司第十届监事会职工监事等职务。现任本公司党委副书记、纪委书记、工 会主席、第十一届董事会职工董事。 除已披露的信息外，胡良玉先生与公司的董事、高级管理人员、公司控股股东、实 际控制人不存在关联关系，未持有公司股份。胡良玉先生不存在《公司法》中规定的不 得担任公司董事的情形；未受过中国证监会和证券交易所任何处罚和惩戒，任职资格符 合担任上市公司董事的条件。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 根据《公司法》《公司章程》的有关规定，上海第一医药股份有限公司（以下简称 "公司"）职工代表大会选举胡良玉先生为公司第十一届董事会职工董事 ...

上海市金茂律师事务所 上海第一医药股份有限公司（以下简称"公司"）2024 年年度股东大会（以 下简称"本次股东大会"）于 2025 年 6 月 20 日在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。上海市金茂律师事务所经公司聘请委派韩春燕律师、 路遥律师（以下简称"本所律师"）出席会议，就本次股东大会的召集、召开程 序，出席会议人员资格，会议议案，以及会议的表决程序、表决结果等发表法律 意见。 本法律意见书根据《中华人民共和国公司法（2023 修订）》（以下简称"《公 司法》"）、《中华人民共和国证券法（2019 修订）》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》（以下简称 "《自律监管指引 1 号》"）等有关法律、法规和规范性文件以及《上海第一医 药股份有限公司章程》（以下简称"《公司章程》"）而出具。 为出具本法律意见书，本所审查了公司本次股东大会的有关文件和材料。本 所得到公司如下保证，即其已提供了本所认为出具本法律意见书所必需的材料， 所提供的原始材料、副 ...